Halozyme Therapeutics (HALO) Intangibles (2022 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Intangibles of $952.0 million for Q1 2026, up 147.86% year-over-year from $384.1 million in Q1 2025, and down 3.01% quarter-over-quarter from $981.5 million in Q4 2025.
Halozyme Therapeutics (HALO) Intangibles (2022 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Intangibles for 5 consecutive years, with $952.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles rose 147.86% year-over-year to $952.0 million; the TTM figure through Mar 2026 stood at $952.0 million (up 147.86% YoY), while the FY2025 annual figure was $981.5 million, up 144.25% from the prior year.
- Intangibles declined to $952.0 million in Q1 2026 per HALO's latest filing, from $981.5 million in the prior quarter.
- Across five years, Intangibles topped out at $981.5 million in Q4 2025 and bottomed at $348.5 million in Q3 2025.
- Historically, Intangibles has averaged $576.3 million across 5 years, with a median of $481.8 million in 2023.
- Annual changes were most pronounced in 2023 — Intangibles plunged 48.29% — and 2026, when it jumped 147.86%.
- Halozyme Therapeutics' Intangibles stood at $546.7 million in 2022, then retreated by 13.5% to $472.9 million in 2023, then slipped by 15.02% to $401.8 million in 2024, then jumped by 144.25% to $981.5 million in 2025, then dropped by 3.01% to $952.0 million in 2026.
- Business Quant data shows HALO's Intangibles at $952.0 million in Q1 2026, $981.5 million in Q4 2025, and $348.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 922.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 922.44 Mn |
| Mar 31, 2026 | 951.96 Mn |
| Dec 31, 2025 | 981.47 Mn |
| Sep 30, 2025 | 348.54 Mn |
| Jun 30, 2025 | 366.31 Mn |
| Mar 31, 2025 | 384.07 Mn |
| Dec 31, 2024 | 401.83 Mn |
| Sep 30, 2024 | 419.59 Mn |
| Jun 30, 2024 | 437.35 Mn |
| Mar 31, 2024 | 455.12 Mn |
| Dec 31, 2023 | 472.88 Mn |
| Sep 30, 2023 | 490.64 Mn |
| Jun 30, 2023 | 510.98 Mn |
| Mar 31, 2023 | 528.82 Mn |
| Dec 31, 2022 | 546.65 Mn |
| Sep 30, 2022 | 948.90 Mn |
| Jun 30, 2022 | 976.10 Mn |